| Safety and efficacy of icatibant self-administration for acute hereditary angioedema. | |
| | |
MedLine Citation:
|
PMID: 22519593 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We evaluated the efficacy and safety of icatibant self-administration in 15 patients with hereditary angioedema (HAE) types I or III, for 55 acute attacks (mostly severe or very severe). Icatibant self-administration was generally effective: first symptom improvement occurred in 5 min-2 h (HAE type I; n = 17) and 8 min-1 h (HAE type III; n = 9) for abdominal attacks and 5-30 min (HAE type I; n = 4) and 10 min-12 h (HAE type III; n = 6) for laryngeal attacks. Complete symptom resolution occurred in 15 min-19 h (HAE type I; n = 8) and 15 min-48 h (HAE type III; n = 9) for abdominal attacks and 5-48 h (HAE type I; n = 3) and 8-48 h (HAE type III; n = 5) for laryngeal attacks. No patient required emergency hospitalization. The only adverse events were mild, spontaneously resolving injection site reactions. Patients reported that carrying icatibant with them gave them greater confidence in managing their condition. |
| | |
Authors:
|
I Boccon-Gibod; L Bouillet |
Related Documents
:
|
21869533 - Association between epicardial adipose tissue volumes on 3-dimensional reconstructed ct... 15466793 - Peripheral high-flow arteriovenous vascular malformations: a single-center experience. 209533 - Pharmacokinetic and therapeutic studies of pivmecillinam in patients with normal and im... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical and experimental immunology Volume: 168 ISSN: 1365-2249 ISO Abbreviation: Clin. Exp. Immunol. Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-04-23 Completed Date: 2012-06-20 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0057202 Medline TA: Clin Exp Immunol Country: England |
Other Details:
|
Languages: eng Pagination: 303-7 Citation Subset: IM |
Copyright Information:
|
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology. |
Affiliation:
|
National Reference Center for Angioedema-CREAK, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France. iboccon-gibod@chu-grenoble.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adult Angioedemas, Hereditary / drug therapy* Bradykinin / administration & dosage, adverse effects, analogs & derivatives* Disease Progression Erythema / etiology Female Humans Male Middle Aged Prospective Studies Quality of Life* Questionnaires Receptors, Bradykinin / antagonists & inhibitors* Self Administration Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Receptors, Bradykinin; 58-82-2/Bradykinin; 7PG89G35Q7/icatibant |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autol...
Next Document: CD137 deficiency does not affect development of airway inflammation or respiratory tolerance inducti...